(生物谷Bioon.com) 原文出处:Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于...
(生物谷Bioon.com) 原文出处:Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,...
MOMENTUM研究中入组的是有治疗应答不足病史的患者,并且一旦出现中度或重度偏头痛发作时就给予治疗;INTERCEPT研究与之不同的是,在偏头痛最早期症状出现时即给予AXS-07治疗。这2项试验证实,与安慰剂和阳性对照药物相比,AXS-07治疗在统计学上显著消除了偏头痛疼痛和最烦人症状。 MOMENTUM研究结果详见:MOMENTUM Phase 3 T...
Symbravo (AXS-07) for Treatment of Acute Migraine in Adults: Phase 3 Trial PrimerHalsey, GracePatient Care (Online)
o阿尔茨海默病烦躁症的AXS-05的Phase 3 ADVANCE-2试验(2024年上半年) o注意力不足多动障碍(ADHD)的solriamfetol的Phase 3 FOCUS试验(2024年下半年) •临床试验启动: o重度抑郁障碍(MDD)的solriamfetol的Phase 3试验(2024年第一季度) o暴食症(BED)的solriamfetol的Phase 3试验(2024年第一季度) ...
Earlier this week, the FDA approved AXS-07, marketed as Symbravo, as a new acute treatment for migraine with or without aura in adults, with supportive data from 2 phase 3 randomized controlled clinical trials—the MOMENTUM trial (NCT03896009) and the INTERCEPT trial (NCT04163185)...
原文出处:Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。
MOMENTUM研究结果详见:MOMENTUM Phase 3 Trial Topline Results。INTERCEPT研究结果详见:INTERCEPT Phase 3 Trial Topline Results。 Axsome首席执行官Herriot Tabuteau医学博士表示:“我们对A类会议的结果非常满意,该会议澄清了我们重新提交AXS-07偏头痛急性治疗NDA的方法。我们感谢FDA深思熟虑的参与,并期待着成功的再次提交...
MoSEIC technology increases the speed of meloxicam absorption while maintaining a long plasma half-life.Design/Methods: MOMENTUM was a Phase 3, single-attack, 4-arm, double-blind, controlled study that randomized 1,594 patients (2:1:2:2) to treatment with AXS-07, placebo (Pbo), MoSEIC ...
Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the Acute Treatment of Migraine: Results from the INTERCEPT Phase 3, Randomized, Double-blind, Placebo-controlled Trial (P14-2.004)Objective: The aim of the INTERCEPT study was to evaluate the efficacy and safety of AXS-07 in...